Improving healthcare for all
4P pharma

BIO-Europe Spring 2021 - 4P Pharma

9 Jan 2021

Disruptiveinnovations in medicine are thriving all around the world, especially in universities and hospitals. However, the number of new drugs entering the development pipeline is dangerously drying up.

As a bridge between academic science and industrial development, 4P-Pharma accelerates innovation. It detects gem projects in order to bring better human health products for patients​. Since 2014, 4P-Pharma has pre-evaluated more than 300 molecules, and carried out a technological due diligence on 18 of them.

Today, 4P-Pharma has incorporated two in clinical-stage asset-centric companies : 4Moving Biotech and 4Living Biotech. 4Moving Biotech focusing on 4P004, a long-term solution to treat Osteoarthritis (OA). Worldwide, 300 million people are affected, 15% of the adult population. 4Living Biotech, focusing on 4P021, a new treatment for patients with severe COVID-19.

4Moving Biotech (4P004) received the Seal of Excellence from the European Commission.

What are you looking for?